Mutations in the SDHA gene are linked to a surprisingly wide spectrum of tumors, most notably paragangliomas, pheochromocytomas, and a specific subset of gastrointestinal stromal tumors (GISTs). The SDHA gene encodes one of four protein subunits that make up an enzyme complex sitting inside your mitochondria, and when it stops working properly, cells can accumulate a molecule called succinate that tricks the body into behaving as though it is starved of oxygen. That chain of events can drive tumor growth in multiple organs, though the overall risk for any single carrier remains lower than many people expect when they first see the mutation on a genetic report.
What the SDHA Gene Actually Does
The SDHA protein is the largest piece of a four-part enzyme called succinate dehydrogenase, also known as mitochondrial complex II. This complex sits at a crossroads of two vital energy-producing pathways: it converts succinate to fumarate as part of the cell’s main fuel-burning cycle (the citric acid cycle), and it simultaneously feeds electrons into the chain that generates most of your cellular energy.1PubMed Central. The genetic basis of isolated mitochondrial complex II deficiency When a mutation knocks out or weakens the SDHA subunit, the whole complex falters, and succinate starts piling up inside the cell.
That buildup matters because succinate is not just inert waste. Excess succinate spills out of the mitochondria and into the main body of the cell, where it interferes with enzymes that normally keep a protein called HIF-1α in check. Under ordinary oxygen levels, HIF-1α gets broken down almost as fast as it is made. But when succinate blocks the enzymes responsible for that breakdown, HIF-1α survives, enters the nucleus, and switches on genes that tell the cell to act as if oxygen is scarce, a state researchers call pseudohypoxia.2PubMed Central. Clinical implications of the oncometabolite succinate in SDHx‐mutation carriers Those genes promote new blood vessel growth, shift the cell’s metabolism, and encourage survival and proliferation, all of which favor tumor development.3Human Molecular Genetics. Mitochondrial succinate is instrumental for HIF1α nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions
On top of pseudohypoxia, succinate accumulation also jams another set of enzymes responsible for removing chemical tags from DNA and the proteins that package it. The result is widespread over-tagging, known as hypermethylation, which silences genes that would otherwise slow cell growth. Studies in mouse cells have shown that this hypermethylation can push cells toward a more mobile, invasive behavior, traits that contribute to tumor progression and metastasis.4PubMed. SDH mutations establish a hypermethylator phenotype in paraganglioma
Paragangliomas and Pheochromocytomas
The tumors most closely associated with SDHA mutations are paragangliomas and pheochromocytomas, collectively referred to as PPGLs. Paragangliomas arise in nerve clusters scattered along the head, neck, chest, and abdomen, while pheochromocytomas grow specifically in the adrenal glands. Both can secrete hormones like adrenaline and noradrenaline, causing episodes of high blood pressure, rapid heartbeat, sweating, and headaches, though some produce no hormones at all and are found incidentally on imaging.
A comprehensive review of reported SDHA-related PPGLs found that these tumors appear across a remarkably wide age range, from 11 to 81 years old, and affect men and women equally. About 91 percent of patients had a single tumor rather than multiple ones. The head and neck were the most common location, accounting for roughly 46 percent of cases, followed closely by the abdomen at around 43 percent, including about 15 percent that were pheochromocytomas. Metastatic disease, where the tumor spreads to distant sites, was documented in about a quarter of cases, with bone and lymph nodes being the most frequent destinations.5PubMed Central. SDHA-related phaeochromocytoma and paraganglioma: review and clinical management
One detail that catches many people off guard is how rarely a family history of SDHA-related tumors shows up. Only about 4 percent of patients in that same review had a known family member with a related tumor.5PubMed Central. SDHA-related phaeochromocytoma and paraganglioma: review and clinical management This low rate of familial clustering reflects the gene’s low penetrance, meaning most people who carry an SDHA mutation will never develop a tumor. That has real implications for how genetic test results are handled, and it can make the counseling conversation confusing for families.
Gastrointestinal Stromal Tumors
GISTs are tumors of the digestive tract wall, and most of them are driven by mutations in genes called KIT or PDGFRA. But a meaningful minority lack those mutations, and within that “wild-type” group, defects in succinate dehydrogenase subunits are a major driver. In a study of wild-type GISTs seen at the NIH, about two-thirds were SDH-mutant, and among those, SDHA mutations were the single most common subunit affected, found in 34 of the 63 SDH-mutant cases.6PubMed Central. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
SDH-deficient GISTs have a distinctive personality. They almost always arise in the stomach, tend to occur in younger patients, and show a female predominance of more than two to one.7PubMed Central. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age They can be multiple rather than solitary and sometimes show a distinctive growth pattern called plexiform muscularis propria involvement. Despite these aggressive-sounding features, many SDH-deficient GISTs have a surprisingly slow, indolent clinical course even when metastatic disease is present at diagnosis.8PubMed Central. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST
That indolence matters for treatment decisions. The standard first-line drug for most GISTs, imatinib, works by blocking KIT and PDGFRA, neither of which is mutated in SDH-deficient tumors. Evidence remains thin that imatinib or similar drugs provide meaningful benefit for these patients, and the absence of targetable KIT or PDGFRA mutations argues against using imatinib routinely.9PubMed Central. Targeted therapy in SDH-deficient GIST Clinicians managing these cases often lean toward watchful waiting or surgery, depending on the tumor’s location, size, and behavior.
Renal Cell Carcinoma and Pituitary Adenomas
Beyond PPGLs and GISTs, SDHA mutations have been reported in kidney cancers and pituitary tumors, though both are rare associations. SDH-deficient renal cell carcinoma is recognized by the World Health Organization as a distinct histological subtype. These kidney tumors tend to be low-grade, with characteristic microscopic features like tubular structures and eosinophilic hyaline bodies surrounded by tumor cells.10PubMed Central. Renal cell carcinoma with succinate dehydrogenase A mutation: A case report and literature review Case reports have documented this association specifically with SDHA variants, but the overall number of reported cases remains small.
Pituitary adenomas linked to SDHA mutations are even rarer. A study screening over 300 pituitary adenomas found only a single case, representing about 0.3 percent, with loss of SDHA staining. That tumor was a prolactin-producing adenoma in a 62-year-old man, and it turned out to involve two separate somatic mutations rather than a germline change.11PubMed Central. Succinate dehydrogenase deficiency is rare in pituitary adenomas There is, however, at least one documented family where a germline SDHA mutation was found in a patient who developed both a paraganglioma and a pituitary adenoma, with both tumors showing loss of SDHA protein.12PubMed. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma So the connection exists, but it appears to be genuinely uncommon.
Carney Triad and Carney-Stratakis Syndrome
Some patients present with combinations of SDH-related tumors in recognizable patterns. Carney triad is a rare syndrome involving paragangliomas, GISTs, and pulmonary chondromas (benign cartilage tumors in the lung). Most cases of Carney triad appear to be driven by epigenetic silencing of the SDHC gene rather than by inherited mutations, but roughly 10 percent of cases are tied to germline variants in one of the SDH subunit genes, including SDHA.13PubMed Central. A case of Carney triad complicated by renal cell carcinoma and a germline SDHA pathogenic variant A related but distinct condition, Carney-Stratakis syndrome (sometimes called Carney dyad), involves the pairing of paragangliomas and GISTs and tends to follow an autosomal dominant inheritance pattern with germline SDH mutations more consistently present.
These syndromes illustrate why clinicians pay attention when a young patient develops a GIST or paraganglioma. The combination of two or more SDH-associated tumors, especially at a young age, can be a signal that a germline mutation is present even when there is no family history of tumors.
SDHA Mutations and Leigh Syndrome
Not all SDHA mutations lead to tumors. In a completely different clinical scenario, children who inherit two defective copies of the SDHA gene, one from each parent, can develop Leigh syndrome, a severe neurological condition that affects the brain’s energy-hungry regions. This is a recessive pattern: one working copy is enough to keep the enzyme functional for basic cellular energy needs, but two broken copies cause the complex to fail outright, starving vulnerable brain tissue of energy.
Leigh syndrome typically appears in infancy or early childhood with progressive loss of motor skills, muscle weakness, breathing difficulties, and distinctive brain lesions visible on MRI. One reported case involved a child found to carry two different SDHA mutations, a nonsense mutation that stops the protein from being made and a missense mutation that produces a faulty version.14PubMed Central. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA) This is important context for genetic counseling: a family discovered to carry an SDHA mutation because of a tumor diagnosis in one member may also carry reproductive implications if both partners happen to be carriers.
Surveillance Recommendations for Carriers
Because SDHA mutation carriers face a low but real lifetime risk of developing PPGLs and potentially GISTs, expert groups have developed surveillance protocols. UK guidelines recommend starting biochemical screening with annual plasma metanephrines, the breakdown products of adrenaline-type hormones, from age 10. Radiological surveillance with MRI of the neck, chest, abdomen, and pelvis is recommended every three to five years starting at age 15. Ultrasound is not considered adequate for this purpose, and routine pituitary imaging is not recommended given how rarely pituitary tumors occur in this population. Predictive genetic testing for family members can be considered around age 10, aligning with when surveillance would begin.15Journal of Medical Genetics. UK recommendations for SDHA germline genetic testing and surveillance in clinical practice
These intervals are notably less intensive than the schedules recommended for carriers of SDHB mutations, which carry a higher risk of aggressive disease. That reflects the current understanding that SDHA mutations have lower penetrance: most carriers will not develop tumors, and the tumors that do occur tend to behave less aggressively on average. Still, the quarter of SDHA-related PPGLs that eventually metastasize is a reminder that surveillance should not be dismissed as unnecessary.
The Challenge of Interpreting SDHA Variants
Multigene panel testing, where dozens of cancer-related genes are sequenced at once, has led to a surge in the detection of SDHA variants in people undergoing genetic testing for unrelated cancers. The clinical interpretation of these variants is often difficult. The gene’s low penetrance means that finding a pathogenic SDHA variant in someone with, say, breast cancer does not necessarily mean the variant caused their cancer or that they face a high risk of developing an SDH-related tumor.16Endocrine-Related Cancer. Comprehensive analysis of germline and somatic SDHA alterations reveals rare incidental germline variants and prognostic implications of somatic loss in breast cancer
Adding to the diagnostic complexity, the SDHA gene has several highly similar pseudogenes, non-functional DNA sequences that look almost identical to the real gene but do not produce a working protein. The short DNA fragments used in standard sequencing technologies can be difficult to distinguish from pseudogene sequences, creating the possibility of false-positive or false-negative results.17American Journal of Clinical Pathology. An Approach for Accurate Molecular Diagnosis of Highly Homologous SDHA Gene Specialized bioinformatic approaches or confirmatory testing may be needed to ensure the mutation call is genuine.
For clinicians and patients navigating an unexpected SDHA finding, the key questions are whether the variant is truly pathogenic, whether it is germline or somatic, and whether it actually explains the patient’s clinical picture. In many cases, the answer is that the variant is real but the immediate clinical impact is uncertain, which can be frustrating for patients who want clear guidance.
How SDHA-Related Tumors Are Identified in the Lab
When a pathologist suspects an SDH-deficient tumor, the first-line tool is immunohistochemistry, staining tumor tissue with antibodies that bind to SDH subunits. Loss of SDHB staining is a general marker of SDH complex dysfunction regardless of which subunit is mutated, because the B subunit becomes unstable when any other subunit is missing. But SDHA mutations have a unique signature: both SDHA and SDHB staining are lost, while tumors with mutations in other subunits typically retain SDHA staining.18PubMed Central. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation This double loss on tissue staining is a strong signal that a germline SDHA mutation may be present and that genetic testing should be offered to the patient.
For GISTs specifically, this immunohistochemical pattern has proven useful. One study showed that all four GISTs lacking SDHA staining harbored the same germline SDHA nonsense mutation, confirming that the staining pattern reliably predicts the genetic finding.19PubMed. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors This kind of straightforward tissue test can spare patients from unnecessary empirical drug treatment and steer them toward appropriate genetic counseling and surveillance.
Emerging Therapeutic Ideas
Standard targeted therapies for GISTs and many other cancers were designed around different molecular targets, so they largely miss the mark for SDH-deficient tumors. But the detailed understanding of how succinate accumulation rewires cell behavior has opened new therapeutic avenues in research. The hypermethylation phenotype driven by succinate, for instance, has prompted interest in drugs that strip methyl groups from DNA or histone proteins, potentially reactivating silenced tumor-suppressor genes. Metabolic reprogramming specific to SDH-deficient cells is also being explored as a potential vulnerability that could be targeted pharmacologically.20Endocrine-Related Cancer. Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas
These approaches remain experimental. For now, management of metastatic SDH-deficient PPGLs and GISTs still relies heavily on surgery, localized radiation for symptomatic tumors, and careful surveillance. Conventional chemotherapy has limited effectiveness against most PPGLs regardless of their genetic background. The hope is that as the biology of succinate-driven tumorigenesis becomes clearer, treatments specifically designed for this pathway will enter clinical trials and eventually standard practice.
Biochemical Clues That Point Toward SDH Mutations
When a patient presents with a paraganglioma or pheochromocytoma, blood and urine tests measuring catecholamine metabolites can sometimes hint at the underlying genetic cause before sequencing is done. Tumors associated with SDHB and SDHD mutations, for example, frequently produce dopamine, and elevated plasma methoxytyramine, the metabolite of dopamine, was seen in about 70 percent of patients with those mutations.21PubMed Central. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma SDHA-related tumors are less well characterized in this regard because they have been studied in smaller numbers, but the biochemical profile can still help narrow the differential and guide genetic testing priorities. Head-and-neck paragangliomas, which are common in SDHA carriers, often produce little or no hormone at all, meaning a normal biochemical result does not rule out the diagnosis.
This is worth knowing because some patients with SDHA-associated PPGLs are diagnosed incidentally, found on imaging done for another reason, rather than through classic hormonal symptoms. That pattern of silent tumors underscores why surveillance programs for known carriers do not rely on symptoms alone but include periodic imaging regardless of how the patient feels.